Objective: To discuss the role of lurbinectedin (Zepzelca) in small cell lung cancer

Agenda:
1. Evolution of Clinical Data and Phase III Program of Lurbinectedin in SCLC:
Understand the developmental journey of lurbinectedin in treating SCLC, from early-phase trials to the pivotal Phase III programs. Gain insights into key clinical data, safety profiles, and efficacy outcomes, and explore the potential implications for the future treatment landscape of SCLC.

2. Real-World Experience: Clinical Practice Learning and Patient Outcomes with Lurbinectedin Treatment for SCLC:
Explore the real-world implementation of lurbinectedin in clinical practice for SCLC. Analyze treatment patterns, patient characteristics, safety, and efficacy. Gain a deeper understanding of how lurbinectedin impacts patient outcomes in a real-world setting.

3. Overcoming Challenges in Treating SCLC Patients:
Learn about the decision-making process in this hard-to-treat aggressive cancer. Extract practical insights and lessons for managing SCLC patients effectively in challenging scenarios.

Disclaimer: This event is exclusively for registered healthcare professionals and students. By submitting this form, you confirm your eligibility within these categories.